SOURCE: Novo Nordisk A/S

May 14, 2008 04:36 ET

Transaction in Own Shares

Novo Nordisk A/S - Share repurchase programme

BAGSVAERD, DENMARK--(Marketwire - May 14, 2008) - Novo Nordisk A/S - Share repurchase programme


On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Since the announcement as of 6 May 2008, the following transactions have been made under the programme:


             Number of Average  Transaction value,
             shares    purchase                  DKK
                        price
Accumulated, 3,242,907                                  1,054,527,638
last
announcement
5 May 2008      25,000 327.2400                             8,181,000
6 May 2008      25,000 328.2000                             8,205,000
7 May 2008      25,000 324.9300                             8,123,250
8 May 2008      25,000 324.6000                             8,115,000
9 May 2008      25,000 325.2500                             8,131,250
Accumulated, 3,367,907                                  1,095,283,138
2008


Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 217,620 B shares. The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 28,079,960 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
                       Tel: (+45) 4442 4765
                       hrmm@novonordisk.com

In North America:      In North America:
Sean Clements          Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   cqfr@novonordisk.com

Stock Exchange Announcement no 26 / 2008





Copyright © Hugin AS 2008. All rights reserved.

Contact Information